Project 461984
Understanding mitochondrial metabolism to identify prostate cancer metabolic vulnerabilities
Understanding mitochondrial metabolism to identify prostate cancer metabolic vulnerabilities
Project Information
| Study Type: | Unclear |
| Research Theme: | Biomedical |
Institution & Funding
| Principal Investigator(s): | Audet-Walsh, Étienne |
| Co-Investigator(s): | Pouliot, Frédéric |
| Institution: | CHU de Québec |
| CIHR Institute: | Cancer Research |
| Program: | |
| Peer Review Committee: | Molecular & Cellular Biology of Cancer |
| Competition Year: | 2022 |
| Term: | 5 yrs 0 mth |
Abstract Summary
Prostate cancer (PCa) is the most common cancer type in males in Western countries. Following surgery or radiotherapy, standards of care for recurrent PCa are to block the androgen receptor (AR), either with androgen deprivation therapy or anti-androgen treatment. Despite positive response initially to these therapies, progression to lethal castration-resistant PCa is inevitable, highlighting the need to develop new approaches to treat this cancer. In the current project, we investigate the possibility to target cell metabolism as a new therapeutic approach.
No special research characteristics identified
This project does not include any of the advanced research characteristics tracked in our database.